The role of cytochrome P450-mediated drug-drug interactions in determining the safety of statins

Bibliography

• LENNERNAS H, FAGER G: Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: similarities and differences. Clin. Pharmacokinet. (1997) 32:403–425.
   PubMed Web of Science ®Google Scholar
• WHITE CM, CHOW MSS: A review of HMG-CoA reductase inhibitors. US Pharmacist. January (1998) HS19-HS30.
   Google Scholar
• Mevacor® prescribing information. Physicians' Desk Reference (Edition 54. Medical Economics Co, Inc., Montvale, NJ (1998):1694–1698.
   Google Scholar
• Zocor® prescribing information. Physicians' Desk Reference(Edition 54. Medical Economics Co, Inc., Montvale, NJ (1998):1776–1780.
   Google Scholar
• Pravachol® prescribing information. Physicians' Desk Reference (Edition 54. Medical Economics Co, Inc., Montvale, NJ (1998):808–811.
   Google Scholar
• Lescol® prescribing information. Physicians' Desk Reference(Edition 54. Medical Economics Co, Inc., Montvale, NJ (1998):1862–1865.
   Google Scholar
• Lipitor® prescribing information. Physicians' Desk Reference (Edition 54. Medical Economics Co, Inc., Montvale, NJ (1998):2186–2189.
   Google Scholar
• BaycolTm prescribing information. Physicians' Desk Reference (Edition 54. Medical Economics Co, Inc., Montvale, NJ (1998):603–606.
   Google Scholar
• HORSMANS Y: Major cytochrome P450 families: implications in health and liver diseases. Acta Castro-Enter. Belgica. (1997) 60:2–10.
   PubMedGoogle Scholar
• MICHALETS EL: Update: clinically significant cytochrome P450 drug interactions. Pharmacotherapy (1998) 18:84–112.
   PubMed Web of Science ®Google Scholar
• CUPP MJ, TRACY TS: Cytochrome P450:New nomenclature and clinical implications. Am. Fain. Phys. (1998) 57:107–116.
   PubMed Web of Science ®Google Scholar
• HANSTEN PD: Understanding drug-druginteractions. Science & Medicine. (1998) January/February:16–25.
   Google Scholar
• LAZAROU J, POMERANZ BH, COREY PN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA (1998) 279:1200–1205.
   PubMed Web of Science ®Google Scholar
• BATES DW, SPELL N, CULLEN DJ et al.FOR THE ADVERSE DRUG EVENTS PREVENTION STUDY GROUP: The costs of adverse drug events in hospitalized patients. JAMA (1997) 277:307–311.
   PubMed Web of Science ®Google Scholar
• DESAGER JP, HORSMANS Y: Clinical pharmacokinetics of 3-hydroxy-3-methylglytaryl-coenzyme A reductase inhibitors. Clin. Pharmacokinet. (1996) 31:348–371.
   PubMed Web of Science ®Google Scholar
• BOBERG M, ANGERBAUER R, FEY P et al.: Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 enzymes involved. Drug Metab. Dispos. (1997) 25:321–331.
   Google Scholar
• TRANSON C, LEEMANN T, VOGT N, DAYER P: In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-) - fluvastatin. Clin. Pharmacal. Ther. (1995) 58:412–417.
   PubMed Web of Science ®Google Scholar
• TRILLI LE, KELLEY CL, ASPINALL SL, KRONER BA: Potential interaction between warfarin and fluvastatin. Ann. Pharmacother. (1996) 30:1399–402.
   PubMed Web of Science ®Google Scholar
• EVERETT DW, CHANDO TJ, DIDONATO GC, SINGHVI SM, PAN HY, WEINSTEIN SH: Biotransformation of pravastatin sodium in humans. Drug Metab. Dispos. (1991) 19:740–748.
   PubMed Web of Science ®Google Scholar
• HATANAKA T: Clinical Pharmacokineticsof Pravastatin. Clin. Pharmacokinet. (2000) 39:397–412.
   PubMed Web of Science ®Google Scholar
• AZIE NE, BRATER DC, BECKER PA, JONES DR, HALL SD: Interaction of diltiazem with lovastatin and pravastatin. Pharmacal. Ther. (1998) 64:369–377.
   Google Scholar
• KANTOLA T, KIVIST KT, NEUVONEN PJ: Effect of itraconazole on the pharmacokinetics of atorvastatin. Pharmacal. Ther. (1998) 64:58–65.
   Web of Science ®Google Scholar
• NEUVONEN PJ, JALAVA KM: Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin. Pharmacal. Ther. (1996) 60:54–61.
   PubMed Web of Science ®Google Scholar
• NEUVONEN PJ, KANTOLA T, KIVIST KT: Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin. Pharmacal. Ther. (1998) 63:332–341.
   PubMed Web of Science ®Google Scholar
• KYRKLUND C, BACKMAN JT et al.: Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin. Pharmacal. Ther. (2000) 68:592–597.
   PubMed Web of Science ®Google Scholar
• SPACH DH, BAUWENS JE, CLARK CD, BURKE WG: Rhabdomyolysis associated with lovastatin and erythromycin use. West. J. Med. (1991) 154:213–215.
   PubMedGoogle Scholar
• ROSENBERG AD, NEUWIRTH MG, KAGEN LJ, SINGH K, FISCHER HD, BERNSTEIN RL: Intraoperative rhabdomyolysis in a patient receiving pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitor. Anesth. Analg. (1995) 81:1089–1091.
   PubMed Web of Science ®Google Scholar
• VEERKAMP JH, SMIT JW, BENDERS AA, OOSTERHOF A: Effects of HMG-CoA reductase inhibitors on growth and differentiation of cultured rat skeletal muscle cells. Biochem. Biophys. Acta. (1996) 1315:217–222.
   PubMedGoogle Scholar
• LEES RS, LEES AM: Rhabdomyolysis from the coadministration of lovastatin and the antifungalagent itraconazole. N Engl. J. Med. (1995) 333:664–665.
   PubMed Web of Science ®Google Scholar
• AYANIAN JZ, FUCHS CS, STONE RM: Lovastatin and rhabdomyolysis. Ann. Intern. Med. (1988) 115:682–683.
   Google Scholar
• BALLANTYNE CM, RADOVANCEVIC B, FARMER JA et al.: Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations. J. Am. Coll. Cordial. (1992) 19:1315–1321.
   PubMed Web of Science ®Google Scholar
• CORPIER CL, JONES PH, SUKI WN et al.: Rhabdomyolysis and renal injury with lovastatin use. JAMA (1988) 260:239–241.
   PubMed Web of Science ®Google Scholar
• AHMAD S: Diltiazem myopathy. Am. Heart J. (1993) 126:1494–1495.
   PubMedGoogle Scholar
• MEIER C, STEY C, BRACK T, MAGGIORINI M, RISTI B, KRAHENBUHL S: [Rhabdomyolysis in patients treated with simvastatin/ cyclosporin: role of the hepatic cytochrome P450 enzyme.] Schweiz. Med. Wochenschr. (1995) 125:1342–1346.
   Google Scholar
• JACOBSON RH, WANG P, GLUECK CJ: Myositis and rhabdomyolysis associated with current use of simvastatin and nefazodone. JAMA (1997) 277:296.
   PubMedGoogle Scholar
• SEGAERT MF, DE SOETE C, VANDEWIELE I, VERBANCK J: Drug-interaction-induced rhabdomyolysis. Nephrol. Dial. Transplant. (1996) 11:1846–1847.
   PubMed Web of Science ®Google Scholar
• US FOOD AND DRUG ADMINISTRATION: FDA Talk Paper. Posicor labeling changes (December 18 1997).
   Google Scholar
• YANG B-B, SIEDLIK PH, SMITHERSJA, SEDMAN AJ, STERN RH: Atorvastatin pharmacokinetic interactions with other CYP3A4 substrates: erythromycin and ethinyl estradiol. Pharm. Res. (1996) 13\(Suppl. 9):S437. Abstract PPDM 8179.
   Google Scholar
• NORMAN DJ, ILLINGWORTH DR, MUNSON J, HOSENPUD J: Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. N Engl. I Med. (1988) 318:46–47.
   PubMed Web of Science ®Google Scholar
• HORN M: Coadministration of itraconazolewith hypolipidemic agents may induce rhabdomyolysis in healthy individuals. Arch. Dermatol (1996) 132:1254.
   PubMed Web of Science ®Google Scholar
• SCHMASSMANN-SUHIJAR D, BULLINGHAM R, GASSER R, SCHMUTZ J, HAEFELI WE: Rhabdomyolysis due to interaction of simvastatin with mibefradil. Lancet (1998) 351:1929–1930.
   PubMed Web of Science ®Google Scholar
• DECOULX E, MILLAIRE A, DE GROOTE P, MAHIEUX G, DUCLOUX G: [Rhabdomyolysis with pravastatin and Type I macrocreatine kinase.] Ann. Cardiol (1993) 42:267–269.
   Google Scholar
• RAGAZZI MB, IACONA I, CAMPANA C et al: Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc. (1993) 25:2732–2734.
   PubMedGoogle Scholar
• MUCK W, MAT I, FRITSCHE L Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Chi]. Pharmacy]. Ther. (1999) 65:251–261.
   PubMed Web of Science ®Google Scholar
• KEOGH A, MACDONALD P, KAAN A, ABOYOUN C, SPRATT P, MUNDY J: Efficacy and safety of pravastatin vs. simvastatin after cardiac transplantation. Heart Lung Transplant. (2000) 19:529–537.
   PubMed Web of Science ®Google Scholar
• PERAULT MC, LADOUCH-BURES L, DEJEAN C, DELAUNAY C, POUGET ABADIE JF, VANDEL B: [Rhabdomyolysis during pravastatin treatment.] Therapie (1993) 48:487.
   PubMedGoogle Scholar
• BIESENBACH G, JANKO O, STUBY U, ZAZGORNIK J: Myoglobinuric renal failure due to long-standing lovastatin therapy in a patient with pre-existing chronic renal insufficiency. Nephrol Dial. Transplant. (1996) 11:2059–2060.
   PubMed Web of Science ®Google Scholar